Gene and cell therapy group Oxford BioMedica has signed a major supply agreement with Novartis.
The agreement covers the commercial and clinical supply of lentiviral vectors used to generate CTL019 (tisagenlecleucel) and other undisclosed Chimeric Antigen Receptor T cell products.
It builds on the collaboration forged between both parties back in October 2014.
Oxford BioMedica could potentially receive in excess of $100 million from Novartis over the next three years.
This amount includes a $10 million upfront payment, various performance incentives and bioprocessing and development services.
The supply agreement is for three years, extendable to five years subject to the agreement of both parties.
In addition, Oxford BioMedica will also receive undisclosed royalties on potential future sales of Novartis’s CAR-T products.